Bitcoin has pushed above the $97,000 level, extending a recovery that has brought short-term relief to a market weighed down by weeks of uncertainty. While the Bitcoin has pushed above the $97,000 level, extending a recovery that has brought short-term relief to a market weighed down by weeks of uncertainty. While the

Bitcoin Reclaims $97K As Long-Term Holders Supply Stays Locked

2026/01/16 10:00

Bitcoin has pushed above the $97,000 level, extending a recovery that has brought short-term relief to a market weighed down by weeks of uncertainty. While the move has reignited optimism among some investors, a large share of analysts remains cautious, arguing that the rally could still be a counter-trend bounce within a broader bearish setup for 2026.

Price strength alone, however, does not fully explain the current move. According to a CryptoQuant analyst, Bitcoin has shown notable resilience after decisively breaking the $94,200 resistance zone and accelerating toward the $97,500 area, with on-chain data offering important context behind the advance.

One of the key indicators supporting this move is Value Days Destroyed (VDD), a metric that sheds light on long-term holder behavior. VDD measures how long coins remained inactive before being spent, weighted by transaction size. In simple terms, it helps distinguish whether price movements are driven by experienced holders distributing old coins or by newer coins changing hands.

As of January 2026, VDD is hovering around 0.53, a historically low reading. This implies that the coins currently moving on the network are relatively young, while older holdings remain largely dormant. Such behavior suggests that long-term holders are not rushing to sell into strength, lending structural support to the recent breakout—even as the broader market debates whether this surge marks renewed strength or merely a temporary reprieve.

Long-Term Holders Reinforce Bitcoin’s Breakout Quality

The report by Carmelo Alemán, Verified On-Chain Analyst at CryptoQuant, highlights an important dynamic behind Bitcoin’s recent move above key resistance levels. Despite the sharp price appreciation, long-term holders remain largely inactive. In practical terms, this means that investors who have held Bitcoin through multiple cycles are not using the current strength as an opportunity to exit positions. Their restraint significantly improves the quality of the rally.

Bitcoin Value Days Destroyed | Source: CryptoQuant

Historically, this behavior has mattered. When Bitcoin advances while Value Days Destroyed (VDD) stays low, it signals that older coins are not entering circulation. Demand is being met primarily by younger supply, allowing price to rise without triggering structural selling pressure from the most experienced market participants. These phases have often aligned with healthier expansion periods rather than short-lived speculative spikes.

The current breakout fits that historical pattern. Bitcoin’s move through resistance has not been accompanied by a surge in long-dormant coins being spent. Instead, long-term capital appears comfortable holding through higher prices, suggesting confidence in the broader market structure rather than urgency to lock in gains.

This supportive backdrop remains conditional. As long as VDD stays suppressed, the rally retains a strong foundation. However, a sustained increase in the indicator would change the narrative, signaling that long-term holders are beginning to distribute and potentially marking a shift toward heavier selling pressure.

Price Tests Key Resistance After December Rebound

Bitcoin price is trying to stabilize after a sharp rebound from the December lows, with the chart showing BTC reclaiming the $96,000–$97,000 zone. This level coincides with a confluence of technical factors, making it a critical area for short-term direction. The recent recovery followed a strong sell-off from the November highs. Where the price broke below the 50-day and 100-day moving averages and briefly capitulated toward the low $80,000s.

BTC testing key Moving Average | Source: BTCUSDT chart on TradingView

From a structure perspective, BTC is now printing higher lows on the daily timeframe, signaling a potential short-term trend reversal. Price has also reclaimed the 50-day moving average, which often acts as dynamic resistance during downtrends. Holding above this level would be constructive, as it suggests buyers are regaining control after weeks of distribution and volatility.

However, overhead resistance remains significant. The 100-day and 200-day moving averages, currently clustered between $100,000 and $108,000, represent a heavy supply zone where previous breakdowns occurred. A failure to push higher could lead to renewed consolidation or a pullback toward the $92,000–$94,000 support range.

Volume has increased during the rebound, showing genuine participation rather than a low-liquidity bounce. Still, the broader trend remains unclear. For bullish momentum, Bitcoin needs acceptance above $97,000 and a clear attempt toward the $100,000 psychological level. Otherwise, the move risks being a technical rebound within a larger corrective phase.

Featured image from ChatGPT, chart from TradingView.com 

Market Opportunity
Belong Logo
Belong Price(LONG)
$0,003627
$0,003627$0,003627
-0,63%
USD
Belong (LONG) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26